Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma

References

• Czauderna P, Lopez-Terrada D, Hiyama E, Haberle B, Malogolowkin MH, Meyers RL. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr 2014; 26:19-28; PMID:24322718; http://dx.doi.org/10.1097/MOP.0000000000000046
   PubMed Web of Science ®Google Scholar
• Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 2009; 361:1662-70; PMID:19846851; http://dx.doi.org/10.1056/NEJMoa0810613
   PubMed Web of Science ®Google Scholar
• Zsiros J, Maibach R, Shafford E, Brugieres L, Brock P, Czauderna P, Roebuck D, Childs M, Zimmermann A, Laithier V, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol 2010; 28:2584-90; PMID:20406943; http://dx.doi.org/10.1200/JCO.2009.22.4857
   PubMed Web of Science ®Google Scholar
• Sivaprakasam P, Gupta AA, Greenberg ML, Capra M, Nathan PC. Survival and long-term outcomes in children with hepatoblastoma treated with continuous infusion of cisplatin and doxorubicin. J Pediatr Hematol Oncol 2011; 33:e226-30; PMID:21792028; http://dx.doi.org/10.1097/MPH.0b013e31821f0eaf
   PubMedGoogle Scholar
• Zsiros J, Brugieres L, Brock P, Roebuck D, Maibach R, Zimmermann A, Childs M, Pariente D, Laithier V, Otte JB, et al. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol 2013; 14:834-42; PMID:23831416; http://dx.doi.org/10.1016/S1470-2045(13)70272-9
   PubMed Web of Science ®Google Scholar
• Grewal S, Merchant T, Reymond R, McInerney M, Hodge C, Shearer P. Auditory late effects of childhood cancer therapy: a report from the children's oncology group. Pediatrics 2010; 125:e938-50; PMID:20194279; http://dx.doi.org/10.1542/peds.2009-1597
   PubMed Web of Science ®Google Scholar
• Knijnenburg SL, Mulder RL, Schouten-Van Meeteren AY, Bokenkamp A, Blufpand H, van Dulmen-den Broeder E, Veening MA, Kremer LC, Jaspers MW. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database Syst Rev 2013; 10:CD008944; PMID:24101439; http://dx.doi.org/10.1002/14651858.CD008944.pub2
   PubMedGoogle Scholar
• Lipshultz SE, Sambatakos P, Maguire M, Karnik R, Ross SW, Franco VI, Miller TL. Cardiotoxicity and cardioprotection in childhood cancer. Acta Haematol 2014; 132:391-9; PMID:25228565; http://dx.doi.org/10.1159/000360238
   PubMed Web of Science ®Google Scholar
• Cairo S, Armengol C, De Reynies A, Wei Y, Thomas E, Renard CA, Goga A, Balakrishnan A, Semeraro M, Gresh L, et al. Hepatic stem-like phenotype and interplay of Wnt/β-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 2008; 14:471-84; PMID:19061838; http://dx.doi.org/10.1016/j.ccr.2008.11.002
   PubMed Web of Science ®Google Scholar
• Lamb J. The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 2007; 7:54-60; PMID:17186018; http://dx.doi.org/10.1038/nrc2044
   PubMed Web of Science ®Google Scholar
• Qu XA, Rajpal DK. Applications of connectivity map in drug discovery and development. Drug Discov Today 2012; 17:1289-98; PMID:22889966; http://dx.doi.org/10.1016/j.drudis.2012.07.017
   PubMed Web of Science ®Google Scholar
• Claerhout S, Lim JY, Choi W, Park YY, Kim K, Kim SB, Lee JS, Mills GB, Cho JY. Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. PLoS One 2011; 6:e24662; PMID:21931799; http://dx.doi.org/10.1371/journal.pone.0024662
   PubMedGoogle Scholar
• Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006; 10:321-30; PMID:17010675; http://dx.doi.org/10.1016/j.ccr.2006.09.005
   PubMed Web of Science ®Google Scholar
• Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW, Opferman JT, Sallan SE, den Boer ML, Pieters R, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006; 10:331-42; PMID:17010674; http://dx.doi.org/10.1016/j.ccr.2006.09.006
   PubMed Web of Science ®Google Scholar
• Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007; 26:5420-32; PMID:17694083; http://dx.doi.org/10.1038/sj.onc.1210610
   PubMed Web of Science ®Google Scholar
• Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007; 1:19-25; PMID:19383284; http://dx.doi.org/10.1016/j.molonc.2007.01.001
   PubMed Web of Science ®Google Scholar
• Hartmann W, Kuchler J, Koch A, Friedrichs N, Waha A, Endl E, Czerwitzki J, Metzger D, Steiner S, Wurst P, et al. Activation of phosphatidylinositol-3′-kinase/AKT signaling is essential in hepatoblastoma survival. Clin Cancer Res 2009; 15:4538-45; PMID:19584164; http://dx.doi.org/10.1158/1078-0432.CCR-08-2878
   PubMed Web of Science ®Google Scholar
• Wagner F, Henningsen B, Lederer C, Eichenmüller M, Gödeke J, Müller-Höcker J, von Schweinitz D, Kappler R. Rapamycin blocks hepatoblastoma growth in vitro and in vivo implicating new treatment options in high-risk patients. Eur J Cancer 2012; 48:2442-50; PMID:22285179; http://dx.doi.org/10.1016/j.ejca.2011.12.032
   PubMed Web of Science ®Google Scholar
• Treppendahl MB, Kristensen LS, Gronbaek K. Predicting response to epigenetic therapy. J Clin Invest 2014; 124:47-55; PMID:24382389; http://dx.doi.org/10.1172/JCI69737
   PubMed Web of Science ®Google Scholar
• Muller BM, Jana L, Kasajima A, Lehmann A, Prinzler J, Budczies J, Winzer KJ, Dietel M, Weichert W, Denkert C. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer–overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer 2013; 13:215; PMID:23627572; http://dx.doi.org/10.1186/1471-2407-13-215
   PubMed Web of Science ®Google Scholar
• Poyet C, Jentsch B, Hermanns T, Schweckendiek D, Seifert HH, Schmidtpeter M, Sulser T, Moch H, Wild PJ, Kristiansen G. Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer. BMC Clin Pathol 2014; 14:10; PMID:24624923; http://dx.doi.org/10.1186/1472-6890-14-10
   PubMedGoogle Scholar
• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6:38-51; PMID:16397526; http://dx.doi.org/10.1038/nrc1779
   PubMed Web of Science ®Google Scholar
• Tomlinson GE, Kappler R. Genetics and epigenetics of hepatoblastoma. Pediatr Blood Cancer 2012; 59:785-92; PMID:22807084; http://dx.doi.org/10.1002/pbc.24213
   PubMed Web of Science ®Google Scholar
• Regel I, Eichenmüller M, Joppien S, Liebl J, Häberle B, Müller-Höcker J, Vollmar A, von Schweinitz D, Kappler R. IGFBP3 impedes aggressive growth of pediatric liver cancer and is epigenetically silenced in vascular invasive and metastatic tumors. Mol Cancer 2012; 11:9; PMID:22401581; http://dx.doi.org/10.1186/1476-4598-11-9
   PubMed Web of Science ®Google Scholar
• Eichenmüller M, Gruner I, Hagl B, Häberle B, Müller-Höcker J, von Schweinitz D, Kappler R. Blocking the hedgehog pathway inhibits hepatoblastoma growth. Hepatology 2009; 49:482-90; PMID:19177589; http://dx.doi.org/10.1002/hep.22649
   PubMed Web of Science ®Google Scholar
• Kim MG, Pak JH, Choi WH, Park JY, Nam JH, Kim JH. The relationship between cisplatin resistance and histone deacetylase isoform overexpression in epithelial ovarian cancer cell lines. J Gynecol Oncol 2012; 23:182-9; PMID:22808361; http://dx.doi.org/10.3802/jgo.2012.23.3.182
   PubMed Web of Science ®Google Scholar
• Rikiishi H, Shinohara F, Sato T, Sato Y, Suzuki M, Echigo S. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Int J Oncol 2007; 30:1181-8; PMID:17390020; http://dx.doi.org/10.3892/ijo.30.5.1181
   PubMed Web of Science ®Google Scholar
• Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation. J Biol Chem 2006; 281:5612-22; PMID:16377638; http://dx.doi.org/10.1074/jbc.M507213200
   PubMed Web of Science ®Google Scholar
• Armeanu S, Pathil A, Venturelli S, Mascagni P, Weiss TS, Gottlicher M, Gregor M, Lauer UM, Bitzer M. Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol 2005; 42:210-7; PMID:15664246; http://dx.doi.org/10.1016/j.jhep.2004.10.020
   PubMed Web of Science ®Google Scholar
• Herold C, Ganslmayer M, Ocker M, Hermann M, Geerts A, Hahn EG, Schuppan D. The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 2002; 36:233-40; PMID:11830335; http://dx.doi.org/10.1016/S0168-8278(01)00257-4
   PubMed Web of Science ®Google Scholar
• Fu M, Wan F, Li Z, Zhang F. 4SC-202 activates ASK1-dependent mitochondrial apoptosis pathway to inhibit hepatocellular carcinoma cells. Biochem Biophys Res Commun 2016; 471:267-73; PMID:26773495; http://dx.doi.org/10.1016/j.bbrc.2016.01.030
   PubMed Web of Science ®Google Scholar
• Venturelli S, Armeanu S, Pathil A, Hsieh CJ, Weiss TS, Vonthein R, Wehrmann M, Gregor M, Lauer UM, Bitzer M. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer 2007; 109:2132-41; PMID:17407132; http://dx.doi.org/10.1002/cncr.22652
   PubMed Web of Science ®Google Scholar
• Yeo W, Chung HC, Chan SL, Wang LZ, Lim R, Picus J, Boyer M, Mo FK, Koh J, Rha SY, et al. Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J Clin Oncol 2012; 30:3361-7; PMID:22915658; http://dx.doi.org/10.1200/JCO.2011.41.2395
   PubMed Web of Science ®Google Scholar
• Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J, Reid JM, Ames MM, Speights R, Ingle AM, et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: a children's oncology group phase I consortium report. J Clin Oncol 2010; 28:3623-9; PMID:20606092; http://dx.doi.org/10.1200/JCO.2009.25.9119
   PubMed Web of Science ®Google Scholar
• Hummel TR, Wagner L, Ahern C, Fouladi M, Reid JM, McGovern RM, Ames MM, Gilbertson RJ, Horton T, Ingle AM, et al. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a children's oncology group phase 1 consortium study. Pediatr Blood Cancer 2013; 60:1452-7; PMID:23554030; http://dx.doi.org/10.1002/pbc.24541
   PubMed Web of Science ®Google Scholar
• Furchert SE, Lanvers-Kaminsky C, Juurgens H, Jung M, Loidl A, Fruhwald MC. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int J Cancer 2007; 120:1787-94; PMID:17230517; http://dx.doi.org/10.1002/ijc.22401
   PubMed Web of Science ®Google Scholar
• Spiller SE, Ravanpay AC, Hahn AW, Olson JM. Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. J Neuro Oncol 2006; 79:259-70; PMID:16645722; http://dx.doi.org/10.1007/s11060-006-9142-0
   PubMed Web of Science ®Google Scholar
• Sonnemann J, Kumar KS, Heesch S, Muller C, Hartwig C, Maass M, Bader P, Beck JF. Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells. Int J Oncol 2006; 28:755-66; PMID:16465382; http://dx.doi.org/10.3892/ijo.28.3.755
   PubMed Web of Science ®Google Scholar
• Munster P, Marchion D, Bicaku E, Lacevic M, Kim J, Centeno B, Daud A, Neuger A, Minton S, Sullivan D. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res 2009; 15:2488-96; PMID:19318486; http://dx.doi.org/10.1158/1078-0432.CCR-08-1930
   PubMed Web of Science ®Google Scholar
• Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, et al. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Br J Cancer 2009; 101:1044-50; PMID:19738609; http://dx.doi.org/10.1038/sj.bjc.6605293
   PubMed Web of Science ®Google Scholar
• Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70:440-6; PMID:20068163; http://dx.doi.org/10.1158/0008-5472.CAN-09-1947
   PubMed Web of Science ®Google Scholar